Long-term management of moderate to severe plaque psoriasis: Maintenance of treatment success following cessation of fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in patients with baseline body surface area of 6%-12%

被引：0

作者：

Gold, Linda Stein ^{[1
]}

Weiss, Jonathan S. ^{[2
]}

Green, Lawrence J. ^{[3
]}

Kircik, Leon ^{[4
]}

Lin, Tina ^{[4
]}

Harris, Susan ^{[5
]}

机构：

[1] Henry Ford Hosp, Detroit, MI 48202 USA

[2] Gwinnett Dermatol PC, Braselton, GA USA

[3] George Washington Univ, Sch Med, Washington, DC 20052 USA

[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[5] Bausch Hlth, Laval, PQ, Canada

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2020年 / 83卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

15324

引用

页码：AB36 / AB36

页数：1

共 19 条

[1] Long-term management of moderate-to-severe plaque psoriasis: Maintenance of treatment success following cessation of halobetasol propionate 0.01%/tazarotene 0.045% lotion
Gold, L. F. Stein
Lebwohl, M. G.
Bhatia, N.
Lin, T.
Pillai, R.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S82 - S82
[2] Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis
Kircik, Leon H.
Papp, Kim A.
Gold, Linda Stein
Harris, Susan
Lin, Tina
Pillai, Radhakrishnan
JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (03) : 279 - 284
[3] Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis
Lebwohl, Mark G.
Gold, Linda Stein
Del Rosso, James Q.
Green, Lawrence
Jacobson, Abby
JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 2068 - 2074
[4] Long-Term Multiple Center Experience in Treating Plaque Psoriasis With Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion
Abduelmula, Abrahim
Gooderham, Melinda J.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2023, 27 (03) : 293 - 294
[5] Halobetasol 0.01%/ tazarotene 0.045% lotion in the treatment of moderate-to-severe plaque psoriasis: Maintenance of therapeutic effect after cessation of therapy
Gold, Linda Stein
Kircik, Leon
Sugarman, Jeffrey
Lin, Tina
Pillai, Radhakrishnan
Varughese, Johnson
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB69 - AB69
[6] Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
Gold, Linda Stein
Lain, Edward
Green, Lawrence J.
Lin, Tina
Israel, Robert
JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (08) : 815 - 820
[7] Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
Pariser, David M.
Green, Lawrence J.
Gold, Linda Stein
Sugarman, Jeffrey L.
Lin, Tina
Pillai, Radhakrishnan
JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (07) : 723 - 726
[8] Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis
Blauvelt, Andrew
Green, Lawrence J.
Lebwohl, Mark G.
Yamauchi, Paul S.
Lin, Tina
Martin, Gina
Pillai, Radhakrishnan
JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (03) : 297 - 299
[9] Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis
Lebwohl, Mark G.
Sugarman, Jeffrey L.
Gold, Linda Stein
Pariser, David M.
Lin, Tina
Pillai, Radhakrishnan
Martin, Gina
Harris, Susan
Israel, Robert
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (01) : 282 - 285
[10] Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study
Lebwohl, M. G.
Stein Gold, L.
Papp, K.
Han, G.
Pariser, D. M.
Lin, T.
Harris, S.
Jacobson, A.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (05) : 1152 - 1160

← 1 2 →